- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01903278
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
24 de setembro de 2015 atualizado por: Cheng jun, Beijing Kawin Technology Share-Holding Co., Ltd.
Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C
This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin(RBV) in the treatment of Chronic hepatitis C who have not been previously treated with Interferon.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Total 720 subjects are divided into two groups and treated separately according to the HCV genotype(genotype 2,3 and non-genotype 2,3).
With 2:1 ratio between experimental group and positive-control group (Peginterferon alfa-2a (Pegasys) plus RBV), 216 subjects for genotype 2,3 and 504 subjects for non-genotype2,3 will be enrolled.
Accordingly, PEG-IFN-SA once weekly and RBV twice a day (bid) are given for 24 weeks and 48 weeks respectively to the HCV genotype 2,3 and the HCV non-genotype 2,3 .
Tipo de estudo
Intervencional
Inscrição (Real)
719
Estágio
- Fase 3
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Beijing, China
- Peking University first hospital
-
Beijing, China
- Beijing Ditan Hospital, Capital Medical University
-
Beijing, China
- Beijing Youan Hospital, Capital Medical University
-
Beijing, China
- Peking University People's Hospital
-
Beijing, China
- 302 Military Hospital of China
-
Beijing, China
- Beijing Youyi Hospital, capital Medical University
-
Beijing, China
- General Hospital of Beijing Military Region
-
Chongqing, China
- The Second Affiliated Hospital of Chongqing Medical University
-
Chongqing, China
- Chongqing Southwest Hospital
-
Shanghai, China
- Shanghai Public Health Clinical Center
-
Tianjin, China
- Tianjin Infectious Disease Hospital
-
-
Gansu
-
Lanzhou, Gansu, China
- First Affiliated Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangzhou Eighth People's Hospital
-
Guangzhou, Guangdong, China
- Nanfang Hospital Southern Medical Unbiversity
-
-
Guangxi
-
Nanning, Guangxi, China
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China
- Third Affiliated Hospital, Hebei Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- The Second Affiliated Hospital of Harbin Medical University
-
-
Henan
-
Xinxiang, Henan, China
- The First Affiliated Hospital of Xinxiang Medical University
-
Zhengzhou, Henan, China
- Henan Provincial People's Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Tongji Hospital, Tongji Medical College Huazhong University of Science & Technology
-
Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University
-
Wuhan, Hubei, China
- Union hospital, Tongji Medical College Huazhong University of Science & Technology
-
-
Hunan
-
Changsha, Hunan, China
- The Second Xiangya Hospital Of Central South University
-
Changsha, Hunan, China
- Xiangya Hospital Central-South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China
- The Second Hospital of Nanjing
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- First Affiliated Hospital of Nanchang University
-
-
Jilin
-
Changchun, Jilin, China
- The First Affiliated Hospital of Jilin University
-
Yanji, Jilin, China
- Yanbian University Hospital (Yanbian Hospital)
-
-
Liaoning
-
Shenyang, Liaoning, China
- The Sixth People's Hospital of Shenyang
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- First Affiliated Hospital Of Medical College of Xian Jiaotong University
-
Xi'an, Shaanxi, China
- Second Affiliated Hospital Of Medical College of Xian Jiaotong University
-
Xi'an, Shaanxi, China
- Tangdu hospital,fourth military medical university
-
-
Shandong
-
Jinan, Shandong, China
- Qilu Hospital Of Shandong University
-
Jinan, Shandong, China
- Jinan Infectious Disease Hospital
-
Qingdao, Shandong, China
- Qingdao Municipal Hospital
-
-
Shanxi
-
Taiyuan, Shanxi, China
- The First Hospital of Shanxi Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, China
- Sichuan Academy of Medical Science &Sichuan Provincial People's Hospital
-
-
Xinjiang
-
Urumqi, Xinjiang, China
- The First Teaching Hospital of Xinjiang Medical University
-
-
Zhejiang
-
Wenzhou, Zhejiang, China
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 65 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Age 18- 65 years
- Body Mass Index (BMI) 18-30
- Chronic hepatitis C , diagnosed according to Chinese guideline of Hepatitis C (year 2004)
- Detectable serum HCV-RNA by quantitative polymerase chain reaction assay and positive anti-HCV antibody
- Female subjects of childbearing age with no history of menopause and negative pregnancy test, both female and male( including their partners ) subjects were required to conduct adequate contraception since screening until the 6 months after treatment
- Volunteered to participate in this study, understood and signed an informed consent
Exclusion Criteria:
- Previous IFN treated patients
- Hepatotoxic drugs was systematically used more than two weeks within past 6 months
- Systemic therapy with potent immunomodulatory agents such as adrenocorticotropic hormone, thymosin α1, etc more than two weeks within past 6 months, not including corticosteroid nasal sprays, inhaled steroids and / or topical steroids
- Co-infection with HAV, HBV, HEV, EBV, CMV and HIV
- Evidences of hepatic decompensation, including but not limited to serum total bilirubin> 2 times the upper limit of normal (ULN); serum albumin <35g/L; prothrombin activity (PTA) <60%; ascites, upper gastrointestinal bleeding and hepatic encephalopathy; Child-Pugh score B/C grade
- Diagnosed with primary hepatocellular carcinoma or supported by evidences including but not limited to AFP> l00ng/ml, suspicious liver nodules by imaging examinations
- Liver diseases from causes other than HCV infection, including alcoholic liver disease, non-alcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis (antinuclear antibody titer higher than 1:100), hepatolenticular degeneration (Wilson's disease) and hemochromatosis, etc.
- White blood cell count <3×109/L; Neutrophil count<1.5×109/L; platelet count<90×109/L; hemoglobin below the lower limit of normal
- Serum creatinine above the ULN
- Serum creatine kinase> 3 ULN
- Diabetes mellitus or Poorly controlled Thyroid Diseases
- Poorly controlled hypertension (systolic blood pressure> 140mmHg, or diastolic blood pressure> 90 mmHg) with hypertension -related retinal lesions
- Immunodeficiency or autoimmune diseases including but not limited to inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, scleroderma, Sjogren's syndrome, autoimmune thrombocytopenia, etc.
- Psychiatric and nervous system disorders, including history of Psychiatric illness or with family history (especially depression, depressive tendencies, epilepsy and hysteria, etc.)
- Severe cardiovascular diseases (New York Heart Association functional class (NYHA) Ⅲ level and above, myocardial infarction occurred within past 6 months or PTCA performed within past 6 months, unstable angina, uncontrolled arrhythmias)
- Serious blood disorders (all kinds of anemia, hemophilia, etc.)
- Severe kidney disease (chronic kidney disease, renal insufficiency, etc.)
- Serious digestive diseases (gastrointestinal ulcers, colitis, etc.)
- Severe respiratory disease (pneumonia, chronic obstructive pulmonary disease, interstitial lung disease, etc.)
- Retinal disease (retinal exfoliation, macular hole, retinal tumors, etc.)
- Malignancies
- Function organs transplant
- Allergies or severe allergies, especially allergic to study drugs or any ingredients of the study drugs
- Evidence of alcohol or drug abuse (average alcohol consumption male> 40g / day, female> 20g / day)
- Pregnant or lactating women
- Usage of prohibition drugs in this study
- Participated in other clinical trials 3 months prior to the screening
- Unwilling to sign the informed consent and adhere to treatment requirements
- Other conditions not suitable for study judged by investigators
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: PEG-IFN-SA /RBV T1(Genotype2,3)
PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid(BW<75kg,1000mg/d; BW≥75kg, 1200mg/d),24 weeks
|
|
Comparador Ativo: Pegasys /RBV C1(Genotype 2,3)
Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),(BW<75kg,1000mg/d;BW≥75kg,1200mg/d)for 24 weeks
|
|
Experimental: PEG-IFN-SA /RBV T2(Non-genotype 2,3)
PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),(BW<75kg,1000mg/d;BW≥75kg,1200mg/d)for 48 weeks
|
|
Comparador Ativo: Pegasys /RBV C2(Non-genotype 2,3)
Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),(BW<75kg,1000mg/d;BW≥75kg,1200mg/d)for 48 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
SVR (sustained virologic response)
Prazo: 24 weeks after 24 or 48 weeks of study therapy
|
defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at 24 weeks after the end of SVR (sustained virologic response) defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at 24 weeks after the end of treatment
|
24 weeks after 24 or 48 weeks of study therapy
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
RVR(rapid virologic response)
Prazo: weeks 4 of study therapy
|
defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at weeks 4
|
weeks 4 of study therapy
|
cEVR (complete early virologic response)
Prazo: weeks 12 of study therapy
|
defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at weeks 12
|
weeks 12 of study therapy
|
ETVR( end of treatment virologic response)
Prazo: weeks 24 of study therapy for genotype 2,3, and weeks 48 of study therapy for non-genotype 2,3
|
defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at the end of treatment
|
weeks 24 of study therapy for genotype 2,3, and weeks 48 of study therapy for non-genotype 2,3
|
eRVR ( extended rapid virologic response)
Prazo: weeks 4 and 12 of study therapy
|
defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at weeks 4 and 12
|
weeks 4 and 12 of study therapy
|
No-responses
Prazo: weeks 12 or weeks 24 of study therapy
|
defined as the proportion of patients who had less than a <2 log IU/ml plasma HCV RNA decline at weeks 12 or had detectable plasma HCV RNA at weeks 24
|
weeks 12 or weeks 24 of study therapy
|
Breakthrough
Prazo: weeks 12, 24 of study therapy for genotype 2,3, and weeks 12, 24 and 48 of study therapy for non-genotype 2,3
|
defined as the proportion of patients who had detectable plasma HCV RNA at any point during treatment after virological response( undetectable plasma HCV RNA)
|
weeks 12, 24 of study therapy for genotype 2,3, and weeks 12, 24 and 48 of study therapy for non-genotype 2,3
|
Relapse
Prazo: 12 and 24 weeks after 24 or 48 weeks of study therapy
|
defined as the proportion of patients who had undetectable HCV RNA at the end of treatment, but reappearance of HCV RNA after the then
|
12 and 24 weeks after 24 or 48 weeks of study therapy
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Cheng jun, MD, PhD, Beijing Ditan Hospital
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de junho de 2013
Conclusão Primária (Real)
1 de agosto de 2015
Conclusão do estudo (Real)
1 de agosto de 2015
Datas de inscrição no estudo
Enviado pela primeira vez
17 de julho de 2013
Enviado pela primeira vez que atendeu aos critérios de CQ
17 de julho de 2013
Primeira postagem (Estimativa)
19 de julho de 2013
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
25 de setembro de 2015
Última atualização enviada que atendeu aos critérios de controle de qualidade
24 de setembro de 2015
Última verificação
1 de setembro de 2015
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças do Fígado
- Infecções por Flaviviridae
- Hepatite, Viral, Humana
- Infecções por Enterovírus
- Infecções por Picornaviridae
- Hepatite
- Hepatite A
- Hepatite C
- Hepatite Crônica
- Hepatite C Crônica
- Agentes Anti-Infecciosos
- Antivirais
- Peginterferon alfa-2a
Outros números de identificação do estudo
- KAWIN-002-2
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Hepatite Crônica C
-
Dokuz Eylul UniversityEge UniversityConcluídoMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CPeru
-
University College CorkDupont Applied BiosciencesRecrutamento
-
Trek Therapeutics, PBCConcluídoHepatite C crônica | Hepatite C Genótipo 1 | Hepatite C (VHC) | Infecção viral da hepatite CEstados Unidos, Nova Zelândia
-
Trek Therapeutics, PBCConcluídoHepatite C crônica | Hepatite C (VHC) | Hepatite C Genótipo 4 | Infecção viral da hepatite CEstados Unidos
-
Humanity and Health Research CentreBeijing 302 HospitalConcluídoInfecção Crônica por Hepatite CChina
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology NetworkConcluídoC. Procedimento CirúrgicoFrança
-
Tripep ABInovio PharmaceuticalsDesconhecidoInfecção Crônica pelo Vírus da Hepatite CSuécia
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsRetiradoInfecção Crônica pelo Vírus da Hepatite CIsrael
-
Hadassah Medical OrganizationDesconhecidoInfecção Crônica pelo Vírus da Hepatite CIsrael
Ensaios clínicos em PEG-IFN-SA /RBV
-
Beijing Kawin Technology Share-Holding Co., Ltd.Concluído
-
National Taiwan University HospitalNational Science Council, Taiwan; Department of Health, Executive Yuan, R.O.C...Rescindido
-
Kirby InstituteJanssen-Cilag Ltd.ConcluídoHepatite C CrônicaAustrália
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedConcluído
-
Beijing Ditan HospitalBeijing YouAn Hospital; Beijing 302 Hospital/5th Medical Center of Chinese PLA...Recrutamento
-
Gilead SciencesConcluídoHepatite CEstados Unidos, Canadá, Reino Unido, Austrália, Nova Zelândia
-
Tibotec BVBAConcluídoHepatite C crônicaFrança, Espanha, Bélgica, Alemanha, Áustria, Holanda
-
Sanjay Gandhi Postgraduate Institute of Medical...Ram Manohar Lohia Institute of Medical Sciences, LucknowRescindido
-
Janssen Infectious Diseases BVBAVertex Pharmaceuticals IncorporatedConcluídoHepatite C CrônicaEstados Unidos, Austrália, Reino Unido, Alemanha, França, Espanha, Bélgica, Holanda, Canadá, Brasil, Porto Rico, Polônia, Suécia, Suíça, Israel
-
Merck Sharp & Dohme LLCConcluídoInfecção Crônica por Hepatite C